GENITOURINARY CANCERS

Leonard Gomella, MD, discusses the future of biomarkers in prostate cancer.

Robert Dreicer, MD, discusses emerging treatments for patients with advanced mCRPC.

The US Preventive Services Task Force (USPSTF) may move away from its long-standing opposition to routine PSA screening for prostate cancer in some men.

Celestia Higano, MD, discusses the early use of chemotherapy, the potential for PARP inhibitors, and the evolving role of radium-223 in prostate cancer. 

Daniel A. Barocas, MD, discusses a study that compared differences in quality of life among patients who have undergone radical prostatectomy, external beam radiotherapy, brachytherapy or active surveillance for low-risk prostate cancer.

Evan Y. Yu, MD, discusses the current treatment options for metastatic urothelial carcinoma, the unmet needs that still exist in this space, and the possibilities for the future treatment landscape.

The antibody-drug conjugate sacituzumab govitecan demonstrated an overall response rate of 31% in heavily pretreated patients with metastatic urothelial cancer.

Susan F. Slovin, MD, PhD, offers her expert insight on the current state of immunotherapy in prostate cancer.

James B. Yu, MD, discusses the current data in support of using moderate hypofractionation in prostate cancer, as well as recent data showing how genomic testing can help with treatment decision making postoperatively.

Andrea Apolo, MD, discusses promising early data demonstrating the activity and safety of cabozantinib and nivolumab, with or without ipilimumab, in bladder cancer and other advanced genitourinary cancers.<br /> &nbsp;

The American Urological Association has announced Ian M. Thompson Jr., MD, has been appointed to the National Cancer Institute&rsquo;s (NCI) Board of Scientific Advisors.

A novel tissue-preserving treatment, padeliporfin vascular-targeted photodynamic therapy, may offer men with low-risk prostate cancer a safe and effective alternative to either active surveillance or radical therapy.

Robert Dreicer, MD, discusses&nbsp;ongoing developments in mCRPC, including the latest approaches with radium-223.

A prostate-specific antigen nadir greater than 0.5 ng/mL following radiation and androgen deprivation therapy seems to identify men prior to PSA failure who are at high-risk for death, and would thus require more aggressive treatment for their prostate cancer.

Tudor Borza, MD,&nbsp;&nbsp;discusses the major findings of his study that found a&nbsp;sharp decline in the overall rate of men receiving treatment for prostate cancer and his stance on the importance of prostate cancer screening and treatment.

Targeted therapies and immunotherapy are revolutionizing oncology, however, chemotherapy retains a key role in the treatment of advanced prostate cancer, with recent data showing profound benefits with docetaxel in newly diagnosed patients.

Michael J. Morris, MD, discusses&nbsp;the use of bone-seeking radiopharmaceuticals in prostate cancer, with a specific focus on radium-223.

The addition of enzalutamide to abiraterone acetate and prednisone failed to improve progression-free survival versus abiraterone and prednisone alone in chemotherapy-na&iuml;ve patients with metastatic castration-resistant prostate cancer who progressed on enzalutamide.

Biomarkers play a key role in the optimization of treatments for patients with prostate cancer. Mark Stein, MD, says that they can even serve as clinical endpoints in trials.

Deepak A. Kapoor, MD, Chairman and CEO of Integrated Medical Professionals, discusses how physicians can adapt to the new value-based payment models.

Renowned oncologist Charles G. Drake, MD, PhD, has joined NewYork-Pesbyterian/Columbia University Medical Center (CUMC).

Raoul Concepcion, MD, director, Comprehensive Prostate Center, discussed the best treatment option for a patient with metasatic castration-resistant prostate cancer (mCRPC) during the LUGPA Annual Meeting.

Raoul Concepcion, MD, director, Comprehensive Prostate Center, recently sat down with <em>Targeted Oncology </em>to discuss his treatment decisions for 2 patient scenarios in prostate cancer.

Mark Stein, MD, medical oncologist, Rutgers Cancer Institute of New Jersey, discusses the future of biomarkers in prostate cancer.

Description of&nbsp;3 cases whereby significant septic complications occurred in the setting of abiraterone use that were associated with&nbsp;hypogammaglobulinemia.